X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Customised Blood Pressure Treatment Can Get More Protection

Content Team by Content Team
13th April 2023
in News, Research & Development
Customised Blood Pressure Treatment Can Get More Protection

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A study from Sweden has gone on to show that patients who have been treated with drugs that are used to lower blood pressure can get better results after changing medications as compared to doubling the dosage of their existing medications. Researchers aimed at investigating if there was an optimal blood pressure drug for every individual that led to a potential treatment for blood pressure.

Notably, four varied blood pressure-lowering drugs were analysed across 280 Swedish patients for over a year. The drugs happened to be tested one after another at several different times during the study. The treatment effect varied to a significant extent for each participant. Professor of Epidemiology at Uppsala University who is also a cardiologist, Johan Sundstrom, the first author of the study, said that certain individuals achieved lower blood pressure from one medication than from another. He added that the effect of a medication change could be twice as big as the effect of doubling the dosage of the current line of drugs.

The classes of drugs for lowering the blood pressure happened to be a diuretic, a calcium channel blocker, an angiotensin receptor blocker, as well as an ACE inhibitor-

  • Lisinopril
  • Candesartan
  • Hydrochlorothiazide
  • Amlodipine

Interestingly, the study’s findings pose a challenge to the strategy that is recommended in the present treatment guidelines.

There were four blood groups that were equally favourable for all patients with high blood pressure.

It is well to note that more than two million Swedes are estimated to have high blood pressure, according to the research. That said, only a fifth of the population was found to control their blood pressure by way of drug therapy. Because of the variety of blood pressure drugs that are available on the market, patients are surely at risk of not getting the optimal drug for the first time. This can undoubtedly lead to poor blood pressure control as well as unnecessary side effects. Therefore, these personalised treatments go on to offer a potential solution.

According to Sundstrom, if they were to personalise each patient’s medication, they could indeed achieve better results and effects than if they were to choose one of the four drug groups randomly.

Notably, individualised treatment provided an extra 4.4 mm Hg in lower systolic blood pressure. Given the right drug for blood pressure, one can get better protection against future cardiovascular diseases in a faster way, said Sundstrom.

Previous Post

Elevating Vaccine Stability Through Predicting mRNA Degrades

Next Post

Research Pins Down New Target To Get Rid of Blood Cancer

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

Research Pins Down New Target To Get Rid of Blood Cancer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In